| PLB-1004 |
PLB-1004 |
Phase 3 Clinical |
Beijing Avistone Pharmaceuticals Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| YK-029A |
YK-029A; YK-209A; YK-209-A; YK-029-A |
Phase 3 Clinical |
Hainan Yuekang Biomedicine Co Ltd |
Drug-Related Side Effects and Adverse Reactions; Carcinoma, Non-Small-Cell Lung |
Details
|
| Olafertinib |
CK-101; RX-518; CS-2481; EGFR-IN-3 |
Phase 3 Clinical |
Suzhou Neupharma Co Ltd |
Lung Diseases; Lung Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Mefatinib |
|
Phase 3 Clinical |
Suzhou Maitai Bio-Technology Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| Cetuximab biosimilar (AlphaMab) |
KN-005 |
Phase 3 Clinical |
Suzhou Alphamab Co Ltd |
Head and Neck Neoplasms; Anus Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms |
Details
|
| MRG-003 |
MRG-003; MRG003 |
Phase 3 Clinical |
|
Head and Neck Neoplasms; Solid tumours; Biliary Tract Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Nasopharyngeal Carcinoma; Bile Duct Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| HA121-28 |
HA121-28; SYHA121-28 |
Phase 3 Clinical |
|
Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Neoplasms; Medullary thyroid cancer (MTC); Bile Duct Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Nimotuzumab biosimilar (El Kendi Pharmaceuticals Manufacturing) |
|
Phase 3 Clinical |
El Kendi Pharmaceuticals |
Uterine Cervical Neoplasms |
Details
|
| Cetuximab biosimilar (AMPO Biotechnology) |
|
Phase 3 Clinical |
Ampo Biotechnology Inc |
Colorectal Neoplasms |
Details
|
| Cetuximab biosimilar (R-Pharm) |
RPH-002 |
Phase 3 Clinical |
R-Pharm |
Head and Neck Neoplasms; Pancreatic Neoplasms |
Details
|
| QL1203 |
QL-1203 |
Phase 3 Clinical |
Qilu Pharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
| BEBT-109 |
BEBT-109 |
Phase 3 Clinical |
Guangzhou BeBetter Medicine Technology Co |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Immunomodulatory progenitor cell therapy (Celixir) |
|
Phase 3 Clinical |
Celixir |
Endomyocardial Fibrosis; Cardiomyopathies |
Details
|
| Izalontamab |
SI-B001; SI-1X6.4 |
Phase 3 Clinical |
|
Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms, Glandular and Epithelial; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| SKLB-1028 |
SKLB-1028 |
Phase 3 Clinical |
Sichuan University, CSPC Pharmaceutical Group Ltd |
Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute |
Details
|
| Varlitinib Ditosylate |
SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 |
Phase 3 Clinical |
Array Biopharma |
Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms |
Details
|
| Becotatug |
JMT-101 |
Phase 3 Clinical |
Shanghai Jmt-Bio Inc |
Solid tumours; Rectal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Izalontamab brengitecan |
BL-B01D1 |
Phase 3 Clinical |
SystImmune |
Nasopharyngeal Carcinoma; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Urologic Neoplasms; Breast Neoplasms; Solid tumours; Digestive System Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms, Fibroepithelial |
Details
|
| Nimotuzumab biosimilar (IBC Generium) |
|
Phase 3 Clinical |
International Biotechnology Center Generium Llc |
Head and Neck Neoplasms |
Details
|
| Depatuxizumab mafodotin |
ABT-414; ABT-414/806 |
Phase 3 Clinical |
Abbvie Inc |
Glioblastoma; Gliosarcoma; Carcinoma, Squamous Cell; Glioma |
Details
|
| EG-007 |
EG-007 |
Phase 3 Clinical |
|
Endometrial Neoplasms |
Details
|
| Larotinib Mesylate |
Z-650 |
Phase 3 Clinical |
Guangdong Dongyangguang Pharmaceutical Co Ltd |
Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma |
Details
|
| Ametumumab |
SY-101 |
Phase 2 Clinical |
Institute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation Army, Shanghai Serum Bio-Technology Co Ltd |
Solid tumours; Colorectal Neoplasms |
Details
|
| BB-401 |
BB-401 |
Phase 2 Clinical |
Benitec Biopharma Ltd |
Squamous Cell Carcinoma of Head and Neck |
Details
|
| Sutetinib Maleate |
|
Phase 2 Clinical |
Jiangsu Maidu Pharmaceutical R & D Co Ltd, Jiangsu Suzhong Pharma Group Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| Petosemtamab |
MCLA-158 |
Phase 2 Clinical |
Merus Nv |
Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Neoplasm Metastasis |
Details
|
| GC-1118A |
GC-1118; GC-1118A |
Phase 2 Clinical |
GC Biopharma Corp |
Solid tumours; Stomach Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis |
Details
|
| Durvalumab/Gefitinib |
|
Phase 2 Clinical |
Medimmune |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Pamvatamig |
MCLA-129 |
Phase 2 Clinical |
Merus Nv |
Solid tumours; Head and Neck Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| JNJ-26483327 |
JNJ-26483327; MTKi-327; BGB-102 |
Phase 2 Clinical |
Johnson & Johnson |
Solid tumours; Neoplasms; Macular Degeneration |
Details
|
| HER-1 vaccine (Center of Molecular Immunology) |
HER1-ECD; HER1-VSSP; HER-1-ECD-VSSP |
Phase 2 Clinical |
Center Of Molecular Immunology |
Neoplasms |
Details
|
| AFM-24 |
AFM-24 |
Phase 2 Clinical |
Affimed |
Solid tumours |
Details
|
| C225-ILS-DOX |
C225-ILs-dox |
Phase 2 Clinical |
Universitaetsspitals Basel |
Breast Neoplasms |
Details
|
| Nazartinib |
EGF-816; EGFRmut-TKI EGF816 |
Phase 2 Clinical |
Novartis Pharma Ag |
Bronchial Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
| Sapitinib |
AZD-8931 |
Phase 2 Clinical |
Astrazeneca Plc |
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis |
Details
|
| Tesevatinib |
XL-647; KD-020; KD-019; EXEL-7647 |
Phase 2 Clinical |
Exelixis Inc |
Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
| Futuximab/Modotuximab |
Sym-004; S95026; S-95026; 992-and-1024 |
Phase 2 Clinical |
Symphogen A/S |
Solid tumours; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Glioma |
Details
|
| DBPR-112 |
ABT-101; DBPR-112 |
Phase 2 Clinical |
National Health Research Institutes |
Solid tumours; Head and Neck Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Panitumumab-IRDye800CW (Stanford University) |
|
Phase 2 Clinical |
Stanford University |
Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Brain Neoplasms |
Details
|
| AMX-3009 Maleate |
AMX-3009; AMX3009马来酸 |
Phase 2 Clinical |
Anrun Medicine Technology (Suzhou) Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
| Allitinib Tosylate |
AST-6; ALS-1306; AST-1306 |
Phase 2 Clinical |
Shanghai Allist Pharmaceutical Technology Co Ltd |
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Demupitamab |
SCT-200 |
Phase 2 Clinical |
SinoCelltech Ltd |
Ovarian Neoplasms; Biliary Tract Neoplasms; Solid tumours; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
| Cetuximab-IRDye800CW (University Medical Center Groningen) |
|
Phase 2 Clinical |
Umcg The University Medical Center Groningen |
Rectal Neoplasms; Small Cell Lung Carcinoma; Penile Neoplasms; Lung Neoplasms |
Details
|
| Selatinib Ditosilate |
QLNC-120 |
Phase 2 Clinical |
Qilu Antibiotics (Linyi) Pharmaceutical Co Ltd, Qilu Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Pimurutamab |
HLX-07 |
Phase 2 Clinical |
Shanghai Henlius Biotech Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Basosquamous; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung |
Details
|
| NRC-2694 |
NRC-2694; NRC-2694A; NRC-2694-A |
Phase 2 Clinical |
Natco Pharma |
Carcinoma; Squamous Cell Carcinoma of Head and Neck |
Details
|
| Bafisontamab |
FIT-013a; EMB-01 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Biliary Tract Neoplasms; Liver Neoplasms; Carcinoid Tumor; Stomach Neoplasms; Neoplasms; Digestive System Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
| Recombinant anti-EGFR chimeric monoclonal antibody (Shanghai CP Guojian) |
CPGJ-602; 602; CPGJ602; CPGJ 602 |
Phase 2 Clinical |
Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd |
Colorectal Neoplasms |
Details
|
| GB-263 |
GB-263; GB-263T |
Phase 2 Clinical |
Genor Biopharma Co Ltd |
Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| ORIC-114 |
ORIC-114; VRN-07 |
Phase 2 Clinical |
Voronoi Inc |
Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| WJ-13404 |
WJ-13404; JS-113; WJ-004 |
Phase 2 Clinical |
Wigen Biomedicine technology (Shanghai) Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| BDTX-1535 |
BDTX-1535 |
Phase 2 Clinical |
Black Diamond Therapeutics Inc |
Glioblastoma; Glioma; Carcinoma, Non-Small-Cell Lung |
Details
|
| Neratinib (Fukang (Shanghai) Health Technology) |
CVL009; CVL-009 |
Phase 2 Clinical |
|
Solid tumours; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| IBI-3001 |
IBI-3001; IBI3001 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours |
Details
|
| TRX-221 |
TRX-221 |
Phase 2 Clinical |
Therapex Corp |
Carcinoma, Non-Small-Cell Lung |
Details
|
| E-EDV-D682 |
PNU-15982; E-EDV-D682; EGFR-EDV-PNU-15982 |
Phase 2 Clinical |
Engeneic Ltd |
Pancreatic Neoplasms |
Details
|
| IBI334 |
IBI334; IBI-334 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| DWP-708 |
DWP-708 |
Phase 2 Clinical |
Daewoong Pharmaceutical Co Ltd |
Acneiform Eruptions |
Details
|
| BBT-207 |
BBT-207 |
Phase 2 Clinical |
Bridge Biotherapeutics Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
| H-002 |
H-002 |
Phase 2 Clinical |
Nanjing Hongyun Biological Technology Co Ltd |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| DAJH-1050766 |
DAJH1050766; DAJH-1050766 |
Phase 2 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
| IAE-0972 |
IAE-0972 |
Phase 2 Clinical |
SunHo (China) BioPharmaceutical Co Ltd |
Solid tumours; Carcinoma, Hepatocellular |
Details
|
| Anti-EGFR CAR-T cell therapy (Beijing Pregene) |
|
Phase 2 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
| BAY-2927088 |
BAY-2927088; BAY2927088 |
Phase 2 Clinical |
Bayer AG, Broad Institute, Harvard University |
Carcinoma, Non-Small-Cell Lung |
Details
|
| HS-10375 |
HS-10375 |
Phase 2 Clinical |
Jiangsu Hansoh Pharmaceutical Group Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| SMET-12 |
SMET-12 |
Phase 2 Clinical |
Zhejiang Shimai Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| EO-1001 |
NT-113; APL-122 |
Phase 2 Clinical |
Edison Pharmaceuticals Inc |
Neoplasms |
Details
|
| TAK-186 |
EGFR x CD3 COBRA; MVC-101; TAK-186 |
Phase 2 Clinical |
Takeda Pharmaceutical Co Ltd |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| AP-L1898 |
JS111; WJ-002; AP-L1898 |
Phase 2 Clinical |
Wigen Biomedicine technology (Shanghai) Co Ltd |
Small Cell Lung Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| BPI-361175 |
BPI-361175 |
Phase 2 Clinical |
Betta Pharmaceuticals Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| CKD-702 |
|
Phase 2 Clinical |
Chong Kun Dang Pharmaceutical Corp |
Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| REGN-7075 |
REGN-7075 |
Phase 2 Clinical |
|
Solid tumours |
Details
|
| JRF-103 |
JRF103; JRF-103 |
Phase 2 Clinical |
Shenzhen Jinrui Foundation Biotechnology Co Ltd |
Solid tumours |
Details
|
| Anti-EGFR-IL-dox (Swiss Group for Clinical Cancer Research) |
|
Phase 2 Clinical |
Schweizerische Arbeitsgemeinschaft Für Klinische Krebsforschung |
Breast Neoplasms |
Details
|
| FCN-411 |
FCN-411 |
Phase 2 Clinical |
Shanghai Fosun Pharmaceutical (Group) Co Ltd |
Small Cell Lung Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Epertinib |
S-222611 |
Phase 2 Clinical |
Shionogi & Co Ltd |
Neoplasms |
Details
|
| Pirotinib Hydrochloride |
KBP-5209 |
Phase 2 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| Humanized anti-EGFR monoclonal antibody (Hualan Biological Engineering/Henan shengming biotechnology) |
|
Phase 2 Clinical |
Henan Shengming Biotechnology Research Institute Co Ltd, Hualan Genetic Engineering Co Ltd |
Colorectal Neoplasms |
Details
|
| Anti-CD3/anti-EGFR -activated T cells (Barbara Ann Karmanos Cancer Institute) |
|
Phase 2 Clinical |
Barbara Ann Karmanos Cancer Institute, University Of Virginia |
Glioblastoma; Pancreatic Neoplasms |
Details
|
| Cetuximab biosimilar (Guilin Sanjin) |
CDP-1; BC-001 |
Phase 1 Clinical |
Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd |
Solid tumours; Neoplasms; Colorectal Neoplasms |
Details
|
| TQB3804 |
TQB-3804 |
Phase 1 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd |
Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| D2C7-based immunotoxins (Duke University) |
D2C7-IT; scds-D2C7 -PE38KDEL; D2C7-(scdsFv)-PE38 KDEL |
Phase 1 Clinical |
Istari Oncology Inc, Duke University |
Glioma |
Details
|
| Anti-EGFR CAR T-cell therapy (Seattle Children's Hospital) |
EGFR-806 |
Phase 1 Clinical |
Seattle Children'S Hospital |
Sarcoma, Synovial; Neoplasms, Germ Cell and Embryonal; Diffuse Intrinsic Pontine Glioma; Retinoblastoma; Neuroblastoma; Sarcoma; Neurofibrosarcoma; Sarcoma, Ewing; Osteosarcoma; Sarcoma, Clear Cell; Rhabdomyosarcoma; Central Nervous System Neoplasms; Wilms Tumor; Carcinoma; Rhabdoid Tumor; Hepatoblastoma; Desmoplastic Small Round Cell Tumor; Diffuse midline glioma; Solid tumours |
Details
|
| BPI-15086 |
BPI-15086; BPI-15000 |
Phase 1 Clinical |
Betta Pharmaceuticals Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Recombinant anti-human EGFR antibody/IL-10 bispecific Fc fusion protein(Dingfu Biotarget) |
CmAb-(IL10)2; DF203; DF-203 |
Phase 1 Clinical |
Dingfu Biotarget Co Ltd |
Solid tumours |
Details
|
| MP-0274 |
DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 |
Phase 1 Clinical |
Molecular Partners Ag |
Neoplasms |
Details
|
| SYN-004 (Synermore Biologics) |
LR-004; SYN-004 |
Phase 1 Clinical |
Lonn Ryonn Pharma Ltd, Synermore Biologics (Suzhou) Co Ltd |
Solid tumours; Carcinoma; Lymphoma, Large B-Cell, Diffuse; Colorectal Neoplasms |
Details
|
| KY-1701 |
KY-1701 |
Phase 1 Clinical |
Jiangsu Kanion Pharmaceutical Co Ltd |
Breast Neoplasms |
Details
|
| Simotinib Hydrochloride |
AL-6802; SIM-6802 |
Phase 1 Clinical |
Jiangsu Simcere Pharmaceutical Co Ltd, Advenchen Laboratories Llc |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Double-deleted Vaccinia Virus Plus CD/ SMR |
JX-929; vvDD-CDSR |
Phase 1 Clinical |
Sillajen Inc |
Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Melanoma |
Details
|
| WSD-0922 |
WSD-0922; WSD0922 |
Phase 1 Clinical |
Wayshine Biopharm International Ltd |
Glioblastoma; Neoplasms; Astrocytoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| TQ-B3395 |
TQ-B3395; CT-1495; TQ-B-3395 |
Phase 1 Clinical |
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd |
Neoplasms; Breast Neoplasms |
Details
|
| Antibody-drug nanocell conjugates (EnGeneIC) |
EGFR-EDV-RRM1; EGFR-EDV-PLK; EGFR-EDV-Dox |
Phase 1 Clinical |
Engeneic Ltd |
Glioblastoma |
Details
|
| Cetuximab biosimilar (Shanghai Henlius Biotech) |
HLX-05; JZB-29; JZB-28 |
Phase 1 Clinical |
Shanghai Henlius Biotech Inc |
Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms |
Details
|
| Recombinant chimeric anti-EGFR monoclonal antibody (Zhejiang Xinwei Shengke Biotechnology) |
|
Phase 1 Clinical |
Zhejiang Xinweishengke Biotechnology Co Ltd |
Esophageal Neoplasms |
Details
|
| Anti-EGFR-bispecific antibody armed activated T-cell therapy (Memorial Sloan Kettering Cancer Center) |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Pancreatic Neoplasms |
Details
|
| [89Zr]Panitumumab |
|
Phase 1 Clinical |
Vanderbilt-Ingram Cancer Center, University Of Alabama At Birmingham, Stanford University |
Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Pancreatic Neoplasms |
Details
|
| Recombinant chimeric anti-EGFR monoclonal antibody (Qilu Pharmaceutical) |
QL-1105 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| EGFRvIII-CAR |
|
Phase 1 Clinical |
Duke University Medical Center |
Glioblastoma |
Details
|
| 14C-labeled poziotinib |
|
Phase 1 Clinical |
Spectrum Pharmaceuticals |
Solid tumours |
Details
|
| BB-101 (Blue Blood Biotech/National Cheng Kung University) |
BB-101 |
Phase 1 Clinical |
National Cheng Kung University, Blue Blood Biotech Corp |
Diabetic Foot |
Details
|
| Puvitinib |
|
Phase 1 Clinical |
Suzhou Teligene Ltd |
Solid tumours |
Details
|
| Betatinib |
TL-512 |
Phase 1 Clinical |
Aspedia Llc, Suzhou Teligene Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| KSP-QRH-E3-IRDye800 |
|
Phase 1 Clinical |
University Of Michigan |
Cholangiocarcinoma |
Details
|
| Hemay-020 |
Hemay-020 |
Phase 1 Clinical |
Tianjin Hemay Pharmaceutical Co Ltd, Hainan General Sanyang Pharmaceutical Co Ltd |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| SGT-210 |
SGT-210 |
Phase 1 Clinical |
Sol Gel Technologies Pte Ltd |
Keratosis |
Details
|
| Epitinib Succinate |
HMPL-813 |
Phase 1 Clinical |
Hutchison Medipharma Ltd |
Solid tumours; Neoplasms; Glioblastoma; Carcinoma, Non-Small-Cell Lung |
Details
|
| ZN-e4 |
ZN-e4; KP-673 |
Phase 1 Clinical |
Zentalis Pharmaceuticals LLC, Zeno Pharma |
Carcinoma, Non-Small-Cell Lung |
Details
|
| LY-01010 |
LY-01010 |
Phase 1 Clinical |
Luye Pharma Group Ltd |
Breast Neoplasms |
Details
|
| PB-357 |
PB-357 |
Phase 1 Clinical |
Pfizer Inc |
Neoplasms |
Details
|
| ZSP-0391 |
ZSP-0391 |
Phase 1 Clinical |
Wuxi Apptec Co Ltd, Guangdong Zhongsheng Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Neptinib Di-P-methylbenzenesulfonate |
|
Phase 1 Clinical |
Shenzhen Neptunus Pharmaceutical Research Institute Co Ltd |
Stomach Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| QRH-882260 |
QRH-882260 |
Phase 1 Clinical |
University Of Michigan |
Cholangiocarcinoma |
Details
|
| Serclutamab talirine |
ABBV-321 |
Phase 1 Clinical |
Abbvie Inc |
Neoplasms |
Details
|
| Recombinant anti-EGFR chimeric antibody (Harbin Pharmaceutical) |
|
Phase 1 Clinical |
Harbin Pharmaceutical Group Holding Co Ltd |
Colorectal Neoplasms |
Details
|
| Diakine-DK2 10 (EGFR) |
DK210; DK-2-10 |
Phase 1 Clinical |
Deka Biosciences Inc |
Kidney Neoplasms; Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Neoplasms; Pancreatic Neoplasms; Skin Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Non-Small-Cell Lung |
Details
|
| HLX-42 |
HLX-42; HLX42 |
Phase 1 Clinical |
Hanlin Biotechnology Co Ltd |
Solid tumours; Neoplasms |
Details
|
| CMAB-017 |
CMAB-017 |
Phase 1 Clinical |
Taizhou Mabtech Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| JY-016 |
JY-016 |
Phase 1 Clinical |
Beijing Jingyitaixiang Technology Development Co Ltd, Beijing Eastern Biotech Co Ltd |
Solid tumours; Colorectal Neoplasms; Lung Neoplasms |
Details
|
| PF-08046052 |
SGN-EGFRd2; LAVA-1223 |
Phase 1 Clinical |
Vu University Medical Center, Lava Therapeutics NV |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
| CM-93 |
CM-93 |
Phase 1 Clinical |
Shanghai Crimson Pharmaceutical Co Ltd |
Glioblastoma |
Details
|
| BLU-701 |
BLU-701; BLU 701 |
Phase 1 Clinical |
Blueprint Medicines Corp |
Carcinoma, Bronchogenic; Carcinoma; Thoracic Neoplasms; Bronchial Neoplasms; Neoplasms; Respiratory Tract Diseases; Lung Diseases; Respiratory Tract Neoplasms; Neoplasms, Nerve Tissue; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma |
Details
|
| CX-904 |
CX-904 |
Phase 1 Clinical |
Amgen Inc, Cytomx Therapeutics Inc |
Solid tumours; Neoplasms |
Details
|
| Cetuximab biosimilar (Humanwell Healthcare) |
|
Phase 1 Clinical |
Humanwell Healthcare (Group) Co Ltd |
Colorectal Neoplasms |
Details
|
| Sirotinib Maleate |
XZP-5491 |
Phase 1 Clinical |
Shandong Xuanzhu Pharmaceutical Technology Co Ltd |
Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
| Tomuzotuximab |
GT-MAB-5.2-GEX |
Phase 1 Clinical |
Glycotope Gmbh |
Solid tumours; Squamous Cell Carcinoma of Head and Neck |
Details
|
| YL-221 |
YL221; YL-221 |
Phase 1 Clinical |
MediLink Therapeutics Co Ltd |
Solid tumours |
Details
|
| [14C]-PLB1004 |
[14C]-PLB1004 |
Phase 1 Clinical |
Beijing Avistone Pharmaceuticals Biotechnology Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| FPI-2107 |
[111In]-FPI-2107 |
Phase 1 Clinical |
|
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
| FPI-2053 |
FPI-2053 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
| CPO-301 |
CPO301; CPO-301 |
Phase 1 Clinical |
CSPC Pharmaceutical Group Ltd |
Solid tumours; Neoplasms; Lung Neoplasms |
Details
|
| FPI-2068 |
[225Ac]-FPI-2068; FPI-2068 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Colorectal Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung |
Details
|
| HS-20117 |
HS-20117; PM1080; PM-1080 |
Phase 1 Clinical |
Biotheus Inc |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| SYS-6010 |
SYS6010; SYS-6010 |
Phase 1 Clinical |
Jushi Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
| SNC-109 |
SNC109; SNC-109 |
Phase 1 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Glioblastoma |
Details
|
| HSK-40118 |
HSK40118; HSK-40118 |
Phase 1 Clinical |
Haisco Pharmaceutical Group Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| AZD9592 |
AZD-9592; AZD9592 |
Phase 1 Clinical |
Astrazeneca Plc |
Solid tumours; Head and Neck Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| JANX-008 |
EGFR-TRACTr; JANX008; JANX-008 |
Phase 1 Clinical |
Janux Therapeutics Inc |
Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| TAVO-412 |
TAVO-412 |
Phase 1 Clinical |
Tavotek Biotherapeutics (Hong Kong) Ltd, Tuochuang Biotechnology (Jiangsu) Co Ltd |
Solid tumours; Neoplasms |
Details
|
| NX-019 |
NX-019 |
Phase 1 Clinical |
Nalo Therapeutics Inc |
Neoplasms |
Details
|
| QLH-11811 |
QLH-11811; QLH11811 |
Phase 1 Clinical |
Qilu Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| Losatuxizumab vedotin |
ABBV-221; ABBV221 |
Phase 1 Clinical |
Abbvie Inc |
Neoplasms |
Details
|
| EGFR/B7H3 CAR-T |
EGFR/B7H3 CAR-T |
Phase 1 Clinical |
Second Affiliated Hospital Of Guangzhou Medical University |
Triple Negative Breast Neoplasms; Lung Neoplasms |
Details
|
| BB-1705 |
BB-1705 |
Phase 1 Clinical |
Bliss Biopharmaceutical (Hangzhou) Co Ltd |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
| CART-EGFR-IL13Ra2 |
CART-EGFR-IL13Ra2; CAR-T-EGFR-IL-13-Ra-2 |
Phase 1 Clinical |
University Of Pennsylvania |
Glioblastoma |
Details
|
| EGFR IL12 CART |
|
Phase 1 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Colorectal Neoplasms |
Details
|
| ERAS-801 |
ERAS-801 |
Phase 1 Clinical |
Regents Of The University Of California |
Glioblastoma |
Details
|
| NIP-142 |
NIP-142 |
Phase 1 Clinical |
National Institutes Of Pharmaceutical Research And Development Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| TAS-2940 |
TAS-2940 |
Phase 1 Clinical |
Taiho Oncology Inc |
Solid tumours; Glioblastoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
| [111In] Panitumumab |
|
Phase 1 Clinical |
Stanford University |
Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck |
Details
|
| BC-3448 |
BC3448; BC-3448 |
Phase 1 Clinical |
|
Solid tumours |
Details
|
| ABBV-637 |
ABBV-637 |
Phase 1 Clinical |
Abbvie Inc |
Solid tumours; Carcinoma, Non-Small-Cell Lung |
Details
|
| M-1231 |
M-1231 |
Phase 1 Clinical |
Emd Serono Research & Development Institute Inc, Merck Serono |
Solid tumours; Esophageal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung |
Details
|
| HLX-35 |
HLX-35 |
Phase 1 Clinical |
Shanghai Henlius Biologics Co Ltd |
Solid tumours; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung |
Details
|
| WTS-004 |
WTS-004 |
Phase 1 Clinical |
Hangzhou Wutong Tree Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| ES-072 |
ES-072 |
Phase 1 Clinical |
Zhejiang Bosheng Pharmaceutical Co Ltd |
Carcinoma, Non-Small-Cell Lung |
Details
|
| ZZ-06 |
ZZ-06 |
Phase 1 Clinical |
Changchun Intellicrown Pharmaceutical Co Ltd |
Solid tumours |
Details
|
| ABY-029 |
ABY-029 |
Phase 1 Clinical |
Dartmouth College, Affibody Ab, Li-Cor Bioscience |
Head and Neck Neoplasms; Sarcoma; Glioma |
Details
|
| Lifirafenib |
BeiGene-283; BGB-283 |
Phase 1 Clinical |
Beigene Ltd |
Solid tumours |
Details
|
| Cetuximab biosimilar (Enzene Biosciences) |
|
Clinical |
Enzene Biosciences Ltd |
Carcinoma, Squamous Cell |
Details
|
| VRN-11 |
VRN11 |
Clinical |
Voronoi Inc |
Carcinoma, Non-Small-Cell Lung |
Details
|
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one. 
A-Z
